Now that Biogen’s aducanumab team and the FDA’s Billy Dunn have been battered by a gamut of angry experts, the analysts are weighing in
On Friday afternoon, some angry and deeply disturbed experts on the FDA advisory panel slapped down Biogen $BIIB and the FDA’s Billy Dunn in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
